Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social FunctioningPRNewsWire • 03/09/23
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual ConferencePRNewsWire • 03/09/23
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual MeetingPRNewsWire • 03/03/23
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma ConferencePRNewsWire • 02/07/23
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023PRNewsWire • 02/06/23
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial ResultsPRNewsWire • 01/17/23
Voyager Therapeutics stock soars, analysts raise price target on new collaboration with Neurocrine Biosciences to advance its gene therapiesProactive Investors • 01/09/23
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological DiseasesGlobeNewsWire • 01/09/23
Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/03/23
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington DiseasePRNewsWire • 12/22/22
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During SleepPRNewsWire • 12/06/22
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022PRNewsWire • 12/02/22
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build BasesInvestors Business Daily • 11/25/22